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ABSTRACT
Synthesis of Resveratrol Ester Derivatives
by
Daniel Lee Ressler

The goal of this research project was to synthesize derivatives of transresveratrol. In
order for resveratrol to be activated and used by the body it needs to bind to Human
Serum Albumin (HSA), a protein in blood plasma. The derivatives were synthesized to
improve the ability of resveratrol to enter cells as well as improve their ability to bind to
HSA. The three derivatives that were synthesized have converted one of the hydroxyl
groups on resveratrol to an ether with a methylene chain terminated by a carboxylic acid.
By varying the lengths of the methylene chain we varied the water solubility of the
resveratrol derivative. This brought the research closer to the goal of determining how
this would affect the binding ability to HSA. Currently three derivatives have been
synthesized and purified once by column chromatography.
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CHAPTER 1
INTRODUCTION
When people seek inspiration, be it for art, philosophy, or math, nature is often
where they turn, and it is no different for chemistry and medicine. The earliest records of
natural products were depicted on clay tablets in cuneiform from Mesopotamia (2600
BC.) which documented oils from Cupressus sempervirens (Cypress) and Commiphora
species (myrrh), both of which are still used to treat coughs, colds, and inflammation.1
According to the World Health Organization (WHO), 80% of people still rely on plantbased traditional medicines for primary health care.2 Today there remains a gap between
modern medical approaches and traditional folk medicine, specifically the legitimacy and
effectiveness of certain treatments. This gap is being closed as the field of medicinal
chemistry evolves and as both chemists and medical professionals investigate various
natural products. The most common example of a natural product is acetylsalicyclic acid,
aspirin, which was derived from the natural product, salicin, that is isolated from the bark
of the willow tree.3 The structures for both salicine and acetylsalicyclic acid can be seen
below in Figure 1.

O
O

HO
HO

OH

OH

O
O

OH
OH

Acetylsalicyclic Acid

Salicin

Figure 1. Chemical structures of various natural products
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Another example of a natural product came from the investigation of Papaver
somniferum L. (opium poppy) which resulted in the isolation of morphine, seen in Figure
2, for use as a commercially important drug, first reported in 1803.4

HO
O

H
N

HO

Figure 2. Chemical structure of morphine
Crucial investigations such as these are often be hindered by the accessibility of
the molecule in question. For instance, in the Netherlands in 1974, C.J. Persons isolated
200 micrograms of periplanone B, a sex excitation pheromone, from the droppings of
75,000 virgin female cockroaches. 5 The chemical structure of periplanone B is shown in
Figure 3. The process of isolating this molecule was extremely time consuming and
clearly illustrated the problems encountered when working with natural products. It was
not until 1979 that chemical synthesis was used as a guide to determine and produce
periplanone B on a large scale in the laboratory.

O

O
O

Figure 3. Chemical structure of periplanone B
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Other challenges when working with natural products could include the size and
complexity of the desired products. Though many natural products contain large carbon
skeletons and diverse functional groups, their total chemical synthesis is important for
investigating and characterizing these molecules.

Polyphenols
To understand the reactivity of polyphenols it is important to understand their
origin. The term polyphenol first appeared in 1894 and was used to describe molecules
derived mainly from plants.6 Phenol, itself, is a compound originally extracted from coal
tar.7 Today, the polyphenol group ranges from natural products to synthetic products.
From the name, it is clear that polyphenols are characterized chemically by the presence
of multiple phenol groups; however, a more rigid definition was created by a group of
chemists, Edwin Haslam, Edgar Charles Bate-Smith, Anthony Swain, and Theodore
White.8 This definition is known as the White-Bate-Smith-Swain-Haslam (WBSSH)
definition of polyphenols and lists four properties that polyphenols must posses:
1) Polyphenols are moderately water soluble compounds
2) Polyphenols have a molecular weight of 500-4,000 Daltons
3) Polyphenols have greater than 12 phenolic hydroxyl groups
4) Polyphenols have 5-7 aromatic rings per 1,000 Daltons
This fairly precise definition was created when polyphenols strictly described a natural
product; since then the definition has changed.
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In 2011, Stéphane Quideau, a chemist, introduced a modified definition stating
that polyphenols should be defined as: compounds exclusively derived from 1) shikimate/
phenylpropanoid and/or 2) the polyketide pathway featuring more than one phenolic unit
and deprived of nitrogen based functionality.9 As the interest in polyphenols grew, this
branch of molecules was further divided into two main groups, hydrolyzable tannins and
phenylpropanoids. Hydrolyzable tannins include gallic acid esters of glucose and other
sugars or cyclitols.10 These tannins continue to attract attention due to their importance in
the process used to tan, or preserve, leather throughout the world. Phenylpropanoids
include lignins, flavonoids, nonflavonoids, and condensed tannins. This group developed
because lignins are important in soil chemistry in addition to plant structure. Furthermore,
flavonoids in this phenylpropanoid group exist as secondary metabolites used for plant
defense and flower color. Flavonoid compounds include (+) catechin and (-) epicatechin,
seen in Figure 4, which have high free radical scavenging activities.
OH

OH
OH
HO

O

HO

O

OH

OH
OH
OH

OH
(+) catechin

(-) epicatechin

Figure 4. Chemical structures of (+) catechin and (-) epicatechin
Several nonflavonoids can be seen in Figure 5 including transpiceid, astringin,
and astringinin; they are very effective free radical scavengers and structural derivatives
of resveratrol.11
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Figure 5. Chemical structures of transpiceid, astringin, and astringinin
As a group, polyphenols undergo several standard reactions that significantly
contribute to their medicinal properties. These reactions include 1) ionization and
oxidations to ortho and para quinones; 2) nucleophilic additions; and 3) oxidative and
hydrolytic bond cleavages. Due to these characteristics, polyphenols tend to have
oxidative activity, although it is not a defining characteristic of the group.
The chemical nature of polyphenols leads to commercial uses. The production of
creosote, with its antiseptic and preservative properties, is widely known for the treatment
and maintenance of wood. Some polyphenols are used as dyes; for example, pomegranate
peels produce colorful fabrics in India, the high level of tannins and other polyphenols
contributing to the color steadfastness. Additionally, polyphenol compounds are used as
hepatotoxins, drugs, also endocrine disruptors and may play a role in the prevention of
degenerative diseases including cardiovascular diseases, cancers, and tooth decay.
Polyphenols are the most abundant antioxidants in our diet. The total dietary
intake may be as high as 1 g/d, 10 times higher than the intake of vitamin C and 100
times higher than the intake of vitamin E.12 Chemists, initially intrigued by the
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antioxidant behavior of polyphenols, focused on antioxidant vitamins, carotenoids, and
minerals. It was not until 1995 that these antioxidant properties began to be more
thoroughly investigated.13 This delay was somewhat because polyphenols are plant
derivatives and, therefore, possess complex molecular structures that were difficult to
reproduce.
The most abundant polyphenols in the environment are the condensed tannins that
are found in almost all families of plants and responsible for up to 50% of the dry weight
of leaves.14 Easily encountered in daily dietary items, polyphenols include many fruits,
vegetables, cereals, chocolate, dry legumes, and plant-based drinks such as fruit juices,
tea, coffee, and red wine. Current research into polyphenols has surged with much focus
on medicinal properties of polyphenols as a group. One of the initial studies that
generated interest around the medicinal properties of polyphenols, including resveratrol,
was published in the 1990s and is known as the French paradox. The French paradox
refers to the inconsistency that while the French traditionally have fatty diets, and many
of them smoke, only a small percentage suffer from coronary heart disease. It was
hypothesized that this phenomenon was directly linked to the French consumption of
wine, specifically red wine. Further investigation revealed the presence of multiple
polyphenolic compounds in red wines, which was potentially overriding the harmful
dietary and lifestyle habits.
Given the vast benefits associated with these polyphenol family, scientists in 1995
began focusing on the medicinal properties of molecules similar to resveratrol, hoping to
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enhance these benefits through chemical derivatives. Many different compounds make up
the polyphenol family. This paper is concentrated on stilbenoids.

Stilbenoids

Stilbenoids are a small group of plant based nutrients and include pterostilbene
and resveratrol. Overall, stilbenoids have anti-inflammatory affects; they prevent cancers
and protect against diabetes. Pterostilbene is a potent antioxidant found mainly in
blueberries, also in grapes. Similarly, resveratrol can be found in grapes and red wines,
with red grapes containing up to 0.78 mg/L of resveratrol.15
In 2008, worldwide it was estimated that there were 12 million new cancer
diagnoses and more than 7 million deaths from cancer.16 A significant amount of research
is in progress exploring methods for prevention of cancer and treatment options. When
looking for new chemo-preventatives, it is not unusual to turn to the natural world for
insight. One molecule of particular interest is resveratrol, first isolated from the roots of
white hellebore plant in 1940.17 Two natural geometric isomers of resveratrol, cis and
trans, exist and can be seen in Figure 6.
OH

OH

HO

HO

OH

transresveratrol

cisresveratrol

Figure 6. Geometric isomers of resveratrol
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The transisomer is the main focus for most research because it mimics calorie
restriction (CR)-type effects on a diverse group of organisms.18 Resveratrol has been
isolated in at least 72 plant species as well as from common foods such as grapes,
mulberries, peanuts, and legumes. Studies indicate resveratrol acts as a phytoalexin, a
compound produced by plants in response to stress from various sources including fungal
infections, UV radiation, and temperature changes.17 Since its discovery in 1940
resveratrol has been found to have numerous health benefits including antioxidant, an
antimutagen, antifungal, antimicrobial, antitumor, and anti-inflammatory properties.19
Due to these many benefits resveratrol has become a molecule of interest in multiple
applications and the number of times it has been referenced has greatly increased since
the 1990s. This growth can be seen in Figure 7.

Figure 7. Citations of resveratrol20
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Antiaging Possibilities
Resveratrol has also been found to have antiaging properties.21 One of the ways
this was discovered was due to resveratrol’s antimicrobial characteristics. Resveratrol
activates sirtuin which has functions including the caloric restriction-longevity effect.21
Another antiaging effect of resveratrol stems from the fact that plants produce resveratrol
when they are under stressful conditions, including UV stress. For that reason, it has also
been demonstrated to play a role in prevention of photoaging.
Photoaging is defined as a characteristic change following chronic UVA and UVB
exposure. Resveratrol has been demonstrated to act on cellular signaling mechanisms
related to UV-mediated photoaging; more specifically, resveratrol lowers the levels of
reactive oxygen species in UVA-exposed HaCat keratinocytes.21
Resveratrol falls into a category known as phytoestrogens. These are being
evaluated as possible selective cytoplasmic and membrane surface estrogen receptor
agonists, which are known to slow skin aging without the potential risk of estrogen.
Further research in this area needs to be conducted; however, estrogen has been
determined to enhance dermal water-holding capacity, to increase glycosaminoglycan
content, to maintain skin elasticity and collagen content, and to diminish wrinkling.21
Antioxidant Properties
A relatively new health trend is concentrated around antioxidants. The ability of
stilbenoids to serve as efficient antioxidants is directly linked to the molecular structure
of the stilbenoid, specifically the location of various hydroxyl groups. Antioxidants are
important because they protect the cells from damage caused by reactive oxygen species
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(ROS). ROS such as superoxide, peroxyl radicals, and hydroxyl radicals form as a natural
byproduct during the metabolism of oxygen and they have important roles in cell
signaling and homeostasis.22 ROS can also be generated from other sources including
ionizing radiation and environmental stress such as UV or heat exposure. An imbalance
between ROS and antioxidants can lead to oxidative stress, which in turn leads to cellular
damage. This type of wide ranging damage has been linked to cancer, aging,
atherosclerosis, ischemic injury, inflammation, and neurodegenerative diseases such as
Alzheimer’s Disease.23 Oxidative stress in the brain, caused by the buildup of betaamyloid plaques, is strongly correlated with the progression of Alzheimer’s disease.24
New research into the relationship between flavonoids and Alzheimer’s disease has found
that epicatchin, a molecule from the family of catechin flavonoids, is able to protect brain
cells, however, not through the originally proposed antioxidant mechanism.25 This study
by McShea et al. showed that epicatchin was present in the bloodstream for a number of
hours after ingestion.25 This suggests that epicatchin is able to last long enough to cross
the blood-brain barrier and could assist in protecting against Alzheimer’s disease.
Effects on Heart Health
When researching resveratrol a reoccurring theme, “the French Paradox”, is often
cited. Epidemiological studies reveal an inverse relationship between heart disease and
flavonoid consumption. A common example of the relationship between flavonoids and
heart disease is often referred to as the French Paradox. Described earlier, this
phenomenon focuses on the trend that French people suffer less from coronary heart
diseases than other Europeans and consume significantly more cholesterol rich foods.
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Many studies investigated this paradox and confirmed that one or two glasses daily of red
wine, which contains high levels of flavonoids mainly quercetin and ruitin, can protect
against heart disease.26 Current work asserts that the flavonoids in red wine play a
significant role in the heart health of many French people.
Some researchers believe that this can be explained by the high quantity of
resveratrol present in red wine, (4-20mg/L).27 It was also found that a wine supplemented
diet was more than twice as effective at reducing serum markers of oxidative stress than a
vegetable-added diet.8
Acknowledged earlier, research has found that resveratrol decreases the risk of
coronary heart attacks by inhibiting platelet aggregation, reducing cholesterol levels, and
displaying anti-inflammatory activity.28 It has also been noted that resveratrol has
protective effects against oxidation of lipoproteins.29 Several projects have investigated
the effects of resveratrol and similar molecules on individuals’ diets. The overall
conclusion is that polyphenols, rather than antioxidant vitamins alone, are responsible for
the antiaging benefits of the Mediterranean diet.
Resveratrol may play a crucial role for the prevention of heart disease because it
has been reported to inhibit platelet aggregation and coagulation.30 Additionally, the
resveratrol molecule displays neurological benefits, allowing it to play a role in
prevention of neurological disorders including strokes, ischemia, Huntington’s disease,
and Alzheimer’s disease.28 Its most exciting attributes, however, are its anticancer
properties. Resveratrol has been shown to inhibit the development of preneoplastic
lesions in carcinogen-treated mouse mammary glands, suggesting it could potentially be a
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cancer chemo-preventative agent in humans. This paper contains a review of current
research regarding resveratrol and its beneficial properties previously mentioned.

Cancer
Cancer comes from the word karcinos, the term Hippocrates used in 400 B.C to
describe tumors.31 A devastating disease, cancer is defined as abnormal cells dividing
uncontrollably as well as invading other tissues. It can spread throughout the body using
either the vascular or the lymphatic systems.
The American Cancer Society has identified more than 100 types of cancer. The
prevalence and magnitude can be illustrated by the most common of which is prostate
cancer with more than 240,000 new cases expected in the United States in 2012.20 Other
predominant cancers include: bladder, breast, colorectal, endometrial, kidney, lung,
pancreatic, and thyroid cancer. Cancers are grouped into five main categories: carcinoma,
sarcoma, leukemia, lymphoma, and myeloma, or central nervous system cancers:
-Carcinoma encompasses cancers that begin in the skin or within tissues that line
internal organs.
-Sarcoma includes cancer that initially starts in connective or supportive tissues
such as bone, cartilage, fat, muscle, or blood vessels.
-Leukemia is a type of cancer that originates in blood-forming tissues, for
example, bone marrow; producing large numbers of abnormal blood cells that
enter the blood stream.
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-Cancers that originally form in cells of the immune system fall into the category
of lymphoma and myeloma. Myelomas, central nervous system cancers, include
those that begin in the tissues of the brain and spinal cord.
While differences in origin dictate the specific type of cancer, all cancers involve the
uncontrolled growth of cells.

Cancer Causes and Prevention
There is a large body of research regarding cancer, with goals to learn more about
its causes, preventions, and treatments. Causes of cancers include genetic predispositions,
tobacco use, diet and physical activity, sun and UV exposure, as well as pollution and
chemical carcinogens. Exploring causality of cancers provides valuable insight into early
prevention. For example, smoking results in approximately 30% of all deaths in the
United States from cancer;32 therefore, by avoid smoking, secondhand smoke, and use of
tobacco products one can prevent some types of cancers.
Another key component of overall good health includes proper diet. Studies have
shown that poor nutritional diet, physical inactivity, and obesity are strongly linked to
cancer; thus, it follows that maintaining good physical health is a means to prevention.
Because the overuse of alcohol increases the risk factors for cancers of the oral cavity,
pharynx, larynx, oesophagus, liver, colo-rectum, and breast, limiting consumption also
falls in the category of proper diet.33
Given the cancer causing damage resulting from sun and UV overexposure,
sunburn and UV protection are crucial for cancer prevention. Though healthy lifestyle

20

choices can lower risk factors for cancer formation, it is important to remember there are
other important contributing factors, such as the ever-present role that genetics plays in
cancer initiation.

Cancer Treatments
In 1846, anesthesia became commonly available to surgeons, resulting in an
increase in the use of surgery as a cancer treatment option.34 As expected, surgery entails
removal of the tumor and often some tissue surrounding or adjacent to the tumor area.
Today treatment selection depends upon the specific form of cancer and its progression.
Current treatment options are sophisticated and widely varied; including targeted therapy,
immunotherapy, hormonal therapy, stem cell or bone marrow transplantation,
hyperthermia, photodynamic therapy, surgery, radiation, and chemotherapy, with each
treatment pathway having inherent drawbacks as well as unique benefits.
Typically physicians and cancer professionals describe a cancer based on when
the cancer was detected and how far it has progressed, referred to as staging. Surgery also
provides a means to verify the presence and stage of cancer. One major drawback to
surgery is the fact that sometimes the cancer is widespread and not all of it can be
removed. For this reason and because of the natural cancer cell growth, surgery is usually
used in tandem with an additional form of treatment.
In 1895 cancer treatment was drastically changed when Wilhelm Conrad
Roentgen invented the x-ray, the resulting technology that would give rise to the option
of radiation therapy for cancer treatment. Radiation therapy uses x-rays to target and kill
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cancer cells. There are several types of radiation therapy, including internal radiation and
proton therapy; the most common is external-beam radiation therapy in which a machine
positioned outside the patient’s body produces and projects the radiation beam.35 One
benefit of radiation therapy is that it is a local treatment, affecting the specific part of the
body receiving the therapy. When used in conjunction with surgery, radiation often
proves effective at initially shrinking a tumor to improve the success of subsequent
surgery. As revolutionary as radiation therapy has been it has many side effects such as
fatigue, mild skin reactions, upset stomach, and loose bowel movements.36 Internal
radiation therapy has been cited as causing bleeding, infections, and irritation after the
implant is removed.36 These are the short-term side effects, with long-term effects
including the risk of a second cancer, infertility, heart problems, gastrointestinal
problems, lung fibrosis, neurologic problems, thyroid problems, or osteoporosis.37
Another cancer treatment, chemotherapy, became available in 1919 when it was
found that a component of mustard gas could reduce white blood cells.38 These
chemotherapeutic drugs halt a cancer cell’s unchecked ability to grow and divide, causing
cell death and reduction of the cancer. Chemotherapy drugs have resulted in more varied
treatment plans using combinations of surgery, radiation, and chemotherapy drugs.
Side effects of chemotherapy depend upon the dosage level and how the patient
reacts to the drugs but typically involve fatigue, risk of infection, nausea, vomiting, loss
of appetite, and diarrhea. While the side effects of these chemotherapy drugs are usually
temporary, disappearing when the treatment is over, all of the current treatments are
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physically and psychologically taxing for the patient; thus, current research focuses on
developing more effective therapeutics with fewer and less severe side effects.

Effects on Cancer
One of the most effective ways to reduce the risk of carcinogenesis once cancer
has been detected is chemo-prevention, i.e., prevention of cancer by ingesting chemical
agents that reduce the risk of carcinogenesis.30 Chemotherapy drugs currently used
include nonsteroidal anti-inflammatory drugs (NSAIDS); these drugs inhibit
cyclooxygenase (COX). COX catalyzes the conversion of arachidonic acid to
proinflammatory chemicals such as prostaglandis which, if present, can stimulate tumor
cell growth and suppress immune surveillance.30 The enzyme can also activate
carcinogens into forms that are able to damage genetic material.
Resveratrol behaves in a similar fashion to the NSAIDS used at this time in that it
inhibits the hydroperoxidase activity of COX-1. The inhibition activity of resveratrol
extends to several human enzymes including F1 ATPase and Tyrosinase.19 Furthermore,
resveratrol can induce quinone reductase activity, significant because quinone reductase
is capable of metabolically detoxifying carcinogens.30
It has been found that resveratrol exerts proapoptotic effect in a discriminatory
fashion. In other words, resveratrol is able to target tumor cells and cause them to die, the
affect is on tumor cells, normal cells remain unharmed. This is especially critical because
many current methods of cancer treatment damage both cancerous cells and normal cells.
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Resveratrol and other wine polyphenols have been shown to act as
chemosensitizers and radiosensitizers, affecting tumor cells with an increased sensitivity
to chemotherapy and radiation. These are exciting and important advances because a
common problem with current cancer treatments is the ability of cancer cells to adapt and
build up resistance to the treatment.
The majority of resveratrol’s benefits stem from the fact that it is an extremely
efficient free radical scavenger. Tests showed that resveratrol was 95% efficient at
preventing lipid peroxidation, compared to 65% efficiency of vitamin E or vitamin C,
which was only 37% efficient.21 Furthermore, other studies indicate that resveratrol is the
most active peroxyl radical scavenging compound when compared to previously known
compounds including catechin, epicatechin, gallocatechin, gallic acid, and ellagic acid.21
Though resveratrol shows potential as a therapeutic in many areas, especially as
an anticancer drug, it not very water-soluble rendering it less effect as a therapeutic drug.
In order for resveratrol to be active, it needs to be bound to Human Serum Albumin
(HSA), protein found in human blood plasma. HSA binds fatty acids, salicylic acids, and
many other commonly used drugs.19 Experiments indicate that the 4’ OH of resveratrol is
the best group for derivatization. It has been shown that HSA has high affinities for
carboxylic acids and that introducing a long chain carboxylate ester group will increase
the binding to HSA.30 There are several projects with the objective of synthesizing
derivatives of resveratrol that have increased binding activity to HSA, which make it a
better anticancer drug.
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Resveratrol
Resveratrol’s health benefits have been known for thousands of years. Both in
ancient India and in ancient China medicines containing resveratrol have been used to
treat a range of conditions from piles and indigestion to intestinal worms. Initially the
molecule, resveratrol was discovered in 1939 by Michio Takaoka, a Japanese scientist but
it was not until the 1990s that research into “the French paradox” caused to resveratrol
studies to really take off. Since then there have been a wide variety of studies focusing on
resveratrol with hopes of understanding why it has such a variety of medicinal properties
as well as how to improve those medicinal properties. It is widely agreed that
resveratrol’s ability to act as an antioxidant gives it many of its medicinal benefits.
Resveratrol’s antioxidant activity can be attributed to its ability as a free radical
scavenger. The hydroxyl groups on resveratrol are what make it such and effective free
radical scavenger. These hydroxyl groups have been studied, and it has been found that
the hydroxyl group in the 4’ position has a pKa of ~9.3 while the other two hydroxyl
groups at 3 and 5 have pKa values of 10.0 and 10.6.39 This difference can be attributed to
the resonance stability that the hydroxyl at 4’ benefits from, which can be viewed below
in schemes 1 and 2.
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Scheme 1. Resonance scheme of resveratrol when 4’ hydrogen is removed
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Scheme 2. Resonance scheme of resveratrol when 3 or 5 hydrogen is removed

As described earlier, resveratrol is an efficient radical scavenger and antioxidant
that is able to reduce ROS, which can lead to a number of problems including developing
Alzheimer’s disease. Oxidative stress is caused by ROS that damage intracellular
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macromolecules in neurons, including proteins, lipids, and DNA, and promote the
dysfunction of various metabolic and signaling pathways in vulnerable brain tissues.40
What makes resveratrol an especially affective antioxidant is that it has three hydroxyl
groups that can donate their proton to a radical species that terminates the activity of the
radicals, coupled with the fact that the now deprotonated resveratrol is a relatively stable
nonreactive species that will not cause intercellular damage. The antioxidant properties of
resveratrol have also been shown to contribute to the preservation of the mitochondria,
which are very susceptible targets of free radical mediated damage.40

Synthesis of Resveratrol
Many synthetic syntheses of resveratrol exist, three of which are represented in
the following schemes. Scheme 3 shows the synthesis of resveratrol using a Wittig
reaction, a common procedure for the synthesis of alkenes.
OMe

OMe
MeO

PPh 3Cl

CHO

nBuLi, THF

+

MeO

MeO

MeO

OMe

H

10%(MeCN) 2PdCl 2

OMe

OMe
94%

Scheme 3. Wittig synthesis of resveratrol
Scheme 4, below, shows the synthesis of resveratrol using a vinylsilane Heck
reaction.
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HO
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1) cat. Pd(dba) 2, KF, nBu 4NCl
2)K2CO3, DMF
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BCl 3(nBu 4N)
OH

OMe

85%

Scheme 4. Vinylsilane Heck synthesis of resveratrol
Scheme 5 shows the synthesis of resveratrol using an optimized Horner-Emmons
reaction.
HO

CO2H

BnO

CO2H

1)BnBr, K 2CO3
OH

2)NaOH/HCl
80%

2)PBr3, pyr. 92%
OBn

PO(O iPr) 2

1)NaOMe, DMF 80%
H

+

Br

P(O iPr) 3
94%

OBn
OH

O
BnO

BnO
1)LAH 82%

HO

2)BBr3 80%

BnO

OBn

OH

Scheme 5. Optimized Horner-Emmons synthesis of resveratrol
These are just a few ways that resveratrol has been synthetically synthesized, each
has its own advantages and disadvantages and there is always a push to develop more
efficient and cost-effective synthesis methods.

Synthesis of Resveratrol Derivatives
Once resveratrol was successfully synthesized the next step was to synthesize
derivatives of resveratrol with the goal of improving its medicinal properties. A few
derivatives can be viewed below in Figure 8. They are separated into two main groups,
methyoxylated derivatives of resveratrol and hydroxylated derivatives of resveratrol.
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Figure 8. Methyoxylated and hydroxylated resveratrol derivatives
Methoxylated derivatives were synthesized with the aim of increasing the
antitumor activity of resveratrol.41 Research has shown that substituting methoxy groups
in place of the hydroxyl groups on resveratrol substantially improved its cytotoxic
activity.42 The hydroxylated derivatives were synthesized based on research that indicated
these hydroxyl groups improved the antiproliferative effects of resveratrol.43,44
Dr. Jiang’s research is focused on improving resveratrol’s anticancer properties,
because of this the derivatives that I synthesized were ethoxylated and methoxylated
derivatives (structures below in Figure 9).
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OH

HO

O
O(CH2)pC OR
1, p = 3 R = CH3
2, p = 5 R = CH2CH3
3, p = 7 R = CH2CH3

Figure 9. Structure of derivatives
Research has indicated that the 4’-OH group plays an important role in
resveratrol’s ability to bind to Human Serum Albumin (HSA) and this is what transports
resveratrol into cells. Improving this binding ability would make resveratrol more
bioavailable and therefore make it a more effective drug to help prevent cancer. The
reason these three derivatives have a long chain is to help improve resveratrol’s water
solubility without changing too much of resveratrol’s chemistry. The goal of this
research, therefore, is to improve resveratrol’s water solubility and its ability to bind to
HSA.
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CHAPTER 2
EXPERIMENTAL
General Methods
All commercial reagents were purchased from Sigma (St.Louis, MO, USA) and
used without further purification. Solvents were used as purchased without further
distillation and are mentioned in the experimental procedures. All proton (1H) and carbon
(13C) nuclear magnetic resonance spectra were recorded with a JEOL-NMR Eclipse
spectrometer operating at 400 MHz and a Varian 400 MHz multinuclear NMR. Chemical
shifts were recorded as delta values in parts per million (ppm) relative to a TMS standard.
The multiplicity for the signal peaks is reported as follows: s, singlet; d, doublet; m,
multiplet. All NMR spectra are available in the appendices. Reported masses were
obtained by using an Ohaus Adventurer Pro balance. Column chromatography was
performed using silica gel as the stationary phase and different mixtures of solvents as
eluents. The composition of these eluent systems are further detailed in the experimental
procedures. Thin layer chromatography (TLC) was performed on silica gel plates using
necessary solvents and visualized under a UVGL-58 UV lamp at 254nm wavelength.
Melting points were determined using MEL-TEMP and recorded without correction.
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Experimental Procedures
Synthesis of (E)-methyl 4-(4-(3,5-dihydroxystyryl)phenoxy)butanoate,1
Figure 10, below, shows the molecular structure of derivative 1.
OH

n=3

HO

O

O
O

Figure 10. Chemical structure of compound 1 (n =3)
Resveratrol (1.1570 g, 5.0692 mmol, 1 equivalent), potassium carbonate (K2CO3)
(0.7590 g, 5.492 mmol, 1.0834 equivalent), and methyl-1-4-bromobutane (C5H9BrO2)
(0.587 mL, 4.65 mmol, .9173 equivalent) were added to a single-neck round bottom flask
(rbf). The reaction was placed under nitrogen (N2), while anhydrous dimethyl sulfoxide
(DMSO) (10 mL) was added using a syringe. The reaction was stirred overnight at room
temperature under N2. The solution was poured onto saturated ammonium chloride
(NH4Cl(aq)) (40 mL ) then extracted with ethyl acetate (EtOAc) (3x30mL). The resulting
organic layer was dried with anhydrous magnesium sulfate, filtered to remove the
magnesium salt, and solvent was evaporated. From the crude product a 0.1002 g portion
was purified by silica column chromatography using a 40% acetone/hexanes as eluent.
Fractions were collected from the column. TLC was used to verify the presence of
desired product based on UV activity, after evaporation of solvents compound 1 was
obtained as a brown powder. (0.0551g, 0.1678 mmol, 55% yield) 1H NMR (400MHz,
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DMSO, δ, ppm), 1.5(triplet), 1.7(pentet), 3.6(singlet), 3.9(triplet), 6.1(singlet),
6.4(singlet), 6.7-7.4(stilbene), 9.2(singlet) 1H NMR of compound 1 can be found in
appendix A.

Synthesis of (E)-ethyl 6-(4-(3,5-dihydroxystyryl)phenoxy)hexanoate,2
Figure 11, below, shows the molecular structure of derivative 2.

OH
n=5
HO
O

O
O

Figure 11. Chemical structure of compound 2 (n=5)
Resveratrol (2.2900 g, 10.033 mmol, 1 equivalent), K2CO3 (1.5180 g, 10.984
mmol, 1.0947 equivalent), and 6-bromohexanoic acid ethyl ester (1.660 mL, 9.369
mmol, .9338 equivalent) were added to a single-neck rbf. The reaction was placed under
nitrogen (N2), then dimethyl sulfoxide (DMSO) (20 mL) was added using a syringe. The
reaction was stirred at room temperature overnight under N2. The solution was then
poured onto saturated NH4Cl(aq) (40 mL) then extracted with EtOAc. The resulting
organic layer was dried with anhydrous magnesium sulfate, filtered to remove the
magnesium salt, and then evaporated. From the crude product a 0.1000 g portion was
purified by silica column chromatography using 20% acetone/hexanes, then the gradient
was increased to a 30% acetone/hexanes. Fractions were collected from the column. TLC
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was used to verify the presence of desired product based on UV activity, after
evaporation of solvents compound 2 was obtained. The product, .0721 g, was
recrystalized from 1:1 EtOAc/Hexane (7mL/7mL) to give compound 2 as a brown
powder (0.0597 g, 0.1661mmol, 60% yield). 1H NMR (400MHz, DMSO, δ, ppm),
1.2(triplet), 1.4(pentet), 1.6(pentet), 1.7(pentet), 2.3(triplet), 3.9(triplet), 4.1(quartet),
6.1(singlet), 6.4(singlet), 6.8-7.0(stilbene), 7.5(doublet), 9.2 (singlet) 1H NMR of
compound 2 can be found in appendix B.

Synthesis of (E)-ethyl 8-(4-(3,5-dihydroxystyryl)phenoxy)octanoate, 3b
Figure 12, below, shows the molecular structure of derivative 3b.
OH

n=7

HO

O

O
O

Figure 12. Chemical structure of compound 3b (n=7)
Procedure for synthesis of compound 3a:
To a single neck rbf, 8-bromooctanoic acid (2.0000 g, 8.9642 mmol, 1 equivalent)
was dissolved in methanol (50 mL), sulfuric acid (1.0 mL, 19 mmol, 2.1195 equivalent)
was slowly added to the reaction and allowed to reflux overnight. After 16 hours, the
reflux was halted, the rbf was cooled to room temperature, the solution was then
concentrated using a rotary evaporator to produce yellowish oil. The yellow oil was
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dissolved in methylene chloride (40 mL), and the solution was washed with saturated
sodium bicarbonate (2 x 30 mL). Another extraction with methylene chloride (20 mL)
was performed on the combined aqueous layers. The combined organic layer was washed
with water and dried over magnesium sulfate. The crude product was obtained after
evaporation of the organic layer. The resulting product was a yellow oil ( 0.70 mL, 0.99
g, 4.4 mmol 50% yield). 1H NMR (400MHz, CCl3D, δ, ppm), 1.3(pentet, 6H),
1.6(pentet, 2H), 1.8(pentet, 2H), 2.3(triplet, 2H), 3.4(triplet, 2H), 3.7(singlet, 3H). 1H
NMR (400MHz, DMSO, δ, ppm), 1.2(pentet, 6H), 1.5(pentet, 2H), 1.8(pentet, 2H),
2.3(triplet, 2H), 3.5(triplet, 2H), 3.6(singlet, 3H). 13C NMR (100MHz, CCl3D, δ, ppm),
25.0, 28.0, 28.3, 28.9, 32.8, 34.0 (2C), 51.6, 170.4 1H NMR of compound 3a can be
found in appendixes E and F, the 13C NMR spectra can be found in appendix G.
Figure 13, below, shows the molecular structure of derivative 3a.

O

Br
O

Figure 13. Chemical structure of compound 3a, Br(CH2)7COOCH3
Procedure for synthesis of compound 3b:
Resveratrol (0.5178 g, 2.269 mmol, 1 equivalent), anhydrous DMSO (5 mL),
K2CO3 (0.3391 g, 2.453 mmol, 1.08 equivalent), and Br(CH2)7COOCH3 (4 mL, 25
mmol) were mixed in a rbf under N2 atmosphere at room temperature for 16 hours. The
solution was then poured onto saturated NH4Cl(aq) (40 mL) solution and extracted with
EtOAc (2x50 mL). The organic layer was dried with anhydrous magnesium sulfate,
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filtered to remove the magnesium salt, and then placed in the hood to dry. A portion of
the resulting product (0.1000 g) was purified by column chromatography. The column
was run as follows, 700 mL of 20% acetone/hexanes followed by 2100 mL of 30%
acetone/hexanes. Fractions were collected from the column after TLC was used to verify
the presence of desired product based on UV activity. After evaporation of solvents
compound 3b was obtained as a light brown powder (0.0716g, 0.186 mmol, 72% yield).
Mp 182-183 0C. 1H NMR (400MHz, DMSO, δ, ppm) 1.2(multiplet, 7H), 1.4(pentet, 2H),
1.6(pentet, 2H), 1.7(pentet, 2H), 2.3(triplet, 2H), 3.9(triplet, 2H), 4.1(quartet, 2H),
6.1(doublet, 1H), 6.4(doublet, 2H), 6.8-7.1 (stilbene, 4H), 7.5 (doublet, 2H), 9.2(singlet,
2H). 13C NMR (100MHz, DMSO, δ, ppm), 14.8, 24.9, 25.7, 29.0 (2C), 34.1, 60.3, 67.9,
102.6, 105.0(2C), 115.3(2C), 127.2, 128.1, 128.4(2C), 130.2(2C), 139.8, 158.9,
159.1(2C), 173.5 1H NMR of compound 3b can be found in appendix C, the 13C NMR
spectra can be found in appendix D and the IR spectra can be found in appendix H.
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CHAPTER 3
RESULTS AND DISCUSSION
Synthesis of (E)-ethyl 8-(4-(3,5-dihydroxystyryl)phenoxy)octanoate, 3b
The three resveratrol derivatives were successfully synthesized and verified using
NMR spectroscopy; however, only derivative 3b was pure enough to be tested in vivo.
The NMR data are presented in the appendixes A through E. The chemical reaction was a
two-step process and is explained below in scheme 6.

Br
O

Sulfuric Acid
OH
+ CH3OH
Reflux 16 hr.

8-Bromooctanoic Acid

O

Br
O

Methyl 8-bromooctanoate

Scheme 6. Synthesis of methyl 8-bromooctanoate
`The first part of the synthesis of compound 3a was a common esterification reaction
which converted 8-bromooctanoic acid to methyl 8-bromooctanoate (Scheme 6). The
product was isolated as a yellow oil that was purified before it was used in the next step
of the synthesis.

OH

OH

HO

+
OH

K 2CO3

DMSO, under N 2

HO

1 hr. r.t

Scheme 7. Reaction conditions for compound 3b
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Scheme 8. Acid-base reaction step of compound 3b
The second part of the synthesis of compound 3 was to replace the desired
hydroxyl group with the 8-bromooctanoate chain (Scheme 9). First the hydroxyl group
needed to be deprotonated by potassium carbonate to make it a better nucleophile.
Literature shows that the three hydroxyl groups of resveratrol, shown in Figure 14, have
different pKa values. Deak et al. discovered that, “...pKa values of 9.3, 10.0, and 10.6...
The first deprotonation step might be assigned to the 4’ -OH’ because the charge of the
corresponding phenolate ion can be delocalized over the whole molecule in this case
only.” 39

HO
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OH
3
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1
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6
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5'

3'
4'
OH

Figure 14. Chemical structure of transresveratrol
Jiang et al. reported preferential deprotonation of the 4’-OH group with potassium
carbonate.19 However, if deprotonation of all three hydroxyl groups is desired
triethylamine is the preferred base because it is a stronger base. Even when potassium
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carbonate is used, side products including the di and tri substituted compounds are
formed besides the major mono-substituted compound. Once the deprotonation is
achieved attaching the 8-bromooctanoate chain is relatively straight forward. DMSO is
favored as an aprotic solvent, which is appropriate for the SN2 reaction

OH

OH

HO

O

+ Br

DMSO, Under N 2 HO

O

O-

O

O

16h

O

Scheme 9. Synthesis of compound 3b
The substitution reaction between the alkyl bromide and the resveratrol phenolate
ion was optimized to give the mono substituted product. The desired mono-substituted
compound was separated from the di- and tri- substituted compounds via column
chromatography.
OH

OH

HO

HO
O

O

+

O

O
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O

Scheme 10. Transesterification reaction
The purity and structure of compound 3b were verified by 1H NMR and 13C
NMR.
1H

NMR of compound 3a in CDCl3 can be found in appendix A. The protons on

this compound are labeled a through e, (see structure Figure 15).
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H f H f H d H d H d H d Hb Hb
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He He Hd Hd Hc Hc

O
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Ha
Ha

Figure 15. Labeled protons of compound 3a
Protons (Ha) appear as a singlet at 3.7 ppm. They are shifted downfield from the normal
alkyl position due to the deshielding effects of the neighboring oxygen. Because (Ha)
protons do not have any vicinal protons, it appears as a singlet peak that integrates to
three protons. Protons (Hb) appears as a triplet at 2.3 ppm that integrates to two protons
and is shifted slightly downfield due to deshielding by the nearby carbonyl. The triplet
splitting for (Hb) occurs because of the two vicinal protons, (Hc). (Hc) Protons gave a
pentet at 1.6 ppm that integrates to two protons and is relatively shielded within the alkyl
chain. The pentet splitting is a result of the four vicinal protons, (Hb) and (Hd). Protons
(Hd) appear as a series of overlapping peaks at 1.3ppm, with the total integration of six
protons. Although these protons are bonded to separate carbons, they are all in chemically
similar environments. Because they are all located towards the center of the alkyl chain,
they are relatively shielded. The pentet for protons (He) occurs at 1.8 ppm and integrates
to two protons. These protons are slightly deshielded compared to the other alkyl protons
because of their proximity to the electronegative bromine atom. The pentet splitting is
due to the four vicinal hydrogens, (Hd) and (Hf). Protons labeled (Hf) appear as a triplet at
3.4 ppm with an integration of two protons. These protons are shifted downfield because
of the deshielding effects of the neighboring bromine. The splitting pattern for these
protons is cause by the two vicinal protons, (He). The 1H NMR of compound 3a in
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DMSO can be found in appendix F, the peaks are slightly shifted in this solvent; however,
they are relatively similar to those in CDCl3.
The 1H NMR of compound 3b can be found in appendix C. The protons are
labeled a through o and the assignments of this compound are shown in Figure 16.
OHn
Ho

Hm

Hl

Hk
Hj
Hi Hi H f H f H e H e H c H c

H nO
Hm

Hl

Hk

O
Hj

Hg Hg He He Hd Hd O

Ha
O
Hb Hb

Ha
Ha

Figure 16. Labeled protons of compound 3b
Protons (Ha and He) showed a multiplet 1.2 ppm, the peaks from Ha form a triplet that
overlaps with the peaks generated by H3. Protons (Hf) show are split into a pentet at
1.4ppm, this splitting is caused by the four neighboring protons (Hg and He). Protons (Hd
and Hg ) are also split into a pentet at 1.6 ppm and 1.7 ppm, perspectively. Protons (Hc)
has two neighboring protons that cause it to form a triplet at 2.3 ppm. While (Hi) protons
gave a triplet at 3.9 ppm. Protons (Hb) generate a quartet at 4.1 ppm. Protons (Ho and Hm)
produce doublets at 6.1 ppm and 6.4 ppm perspectively. The stilbene protons ( Hj, Hk and
Hm ) are found in the aromatic region from 6.8-7.1 ppm. Protons (Hl) generate a doublet
at 7.5 ppm and the singlet at 9.2 ppm corresponds to protons (Hn).
13C

NMR spectrum of Compound 3b is shown in appendix D. The carbons are

labeled a through s on the structure below in Figure 17.
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Figure 17. Labeled carbons of compound 3b
The carbons’ signals are shifted from TMS base on to their chemical
environments. The 13C NMR spectrum accounts for all the carbons further verifying the
molecular structure of compound 3b. As expected, the carbons for the aromatic rings, ( k,
l, m, n, p, q, r and s) can be found from 115-159. The carbons (o) can be found around
127, the alkene region. Carbon (j) is shifted downfield due to its proximity to the oxygen.
The carbonyl carbon (c) is found in the ester region around 173.5. The ethoxy carbons, (a
and b) are shifted downfield because of the neighboring oxygen.
Synthesis of (E)-methyl 4-(4-(3,5-dihydroxystyryl)phenoxy)butanoate, 1
Compound 1 was synthesized with 55% yield and verified by NMR (Appendix
A). However, the purity of the compound was not up to the necessary standards to be
tested in vivo. Because of the impurities, this spectra was not integrated. Future work
with this compound will include purification by column chromatography using a slightly
more polar solvent system, which will help separate out the starting material as well as
the di and tri substituted compounds. The 1H NMR of Compound 1 can be found in
Appendix A. Proton assignments (a through k) of this compound are shown in Figure 18.
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Figure 18. Labeled protons of compound 1
Proton (Ha) gives a singlet found at 3.6ppm, shifted downfield from the normal
alkyl position due to the deshielding effect of the neighboring oxygen. Because (Ha) does
not have any vicinal protons, it appears as a singlet. (Hb) appears as a triplet at 1.5 ppm,
the splitting of this peak is due to the two vicinal protons, labeled as (Hc). (Hc) is a pentet
at 1.7 ppm, split into five due to the four vicinal protons, (Hb and Hd). The protons (Hd)
are shifted downfield as well. Due to their vicinity to the electronegative oxygen, this
peak can be found as a triplet at 3.9 ppm. Because (Hd) is proximal to two vicinal
hydrogens, this peak is split into a triplet. Protons (He, Hf, and Hi) are located in the
aromatic region ranging from 6.7-7.4 ppm. Proton (Hg) is a singlet found at 6.4 ppm. This
remains a singlet as there are no vicinal hydrogens near it. Proton (Hk) is also a singlet
found at 6.1 ppm. Finally (Hj) can be found as a singlet at 9.2 ppm. These protons are the
most downfield due to their direct attachment to oxygen. There are three main impurity
peaks in this spectra, all labeled as “*”, the peak at 9.6 is from resveratrol starting
material and the peaks at 2.3 and 3.4 are from 8-bromooctanoic acid starting material.
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Synthesis of (E)-ethyl 6-(4-(3,5-dihydroxystyryl)phenoxy)hexanoate,2
Compound 2 was synthesized with a 60% yield and verified by NMR, (Appendix
B). The purity of the compound 2 was not up to the necessary standards to continue and
be tested in vivo because of the impurities the NMR spectra was not integrated. Future
work with this compound will include purifying it further using column chromatography
with a slightly more polar solvent system. Once these two compounds are further
purified, tests can be preformed to investigate how the length of the ester chain affects the
molecule’s ability to enter the cell and be used by the body. The 1H NMR of compound 2
can be found in appendix B. Proton assignments (a through n) of this compound are
shown in Figure 19.

OHm
Hn

Hl

Hk

Hj

H mO
Hl

Hk
Hj

Hi
Hg Hg He He Hc Hc
O

O
Hi

Hf Hf H Hd
d

CH3a

O Hb Hb

Figure 19. Labeled protons of compound 2
Protons (Ha) are relatively shielded and occur upfield as a triplet at 1.2 ppm. This
triplet splitting occurs because of the two vicinal protons labeled (Hb). (Hb) appear
downfield at 4.1 ppm due to the deshielding effects of the neighboring oxygen and the
peaks appear as a quartet. The splitting for (Hb) occurs because of the two vicinal protons,
(Ha). (Hc) are slightly deshielded by the neighboring carbonyl which results in the triplet
at 2.3 ppm. The triplet splitting is a result of the two vicinal protons, labeled (Hd). Protons
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(Hd) appear as a pentet at 1.6 ppm. The pentet splitting is due to the four vicinal protons,
(Hc and He). The pentet for (He) occurs at 1.8 ppm, these protons are slightly deshielded,
compared to the other alkyl protons because of their proximity to the electronegative
bromine atom. The pentet splitting is due to the two vicinal hydrogens, (Hd), as well as
the two vicinal hydrogens labeled (Hf). Protons (Hf) appear as a triplet at 3.4 ppm. These
protons are shifted downfield because of the deshielding effects of the neighboring
bromine. The splitting pattern for these protons is caused by the two vicinal protons, (He).
The pentet for (He) occurs at 1.4 ppm and these protons are shielded compared to the
other alkyl protons because of their location towards the center of the alkyl chain. The
pentet splitting is due to the two vicinal hydrogens, (Hd) as well as the two vicinal
hydrogens labeled (Hf). Protons (Hf) appear as a pentet at 1.7 ppm and these protons are
shifted slightly downfield because of the deshielding effects caused by the nearby
oxygen. The pentet splitting pattern for these protons is caused by the four vicinal
protons, (He and Hg). Protons (Hg) are relatively deshielded by the electronegativity of the
neighboring oxygen atom and appear as a triplet at 3.9 ppm. These peaks form a triplet
because of the two vicinal protons (Hf). The (Hi) and (Hl) protons are in a very similar
chemical environment due to the conjugation within the molecule, thereby appearing as a
stillbene multiplet between 6.9-7.0 ppm. The (Hi) protons should appear as a doublet in
the aromatic region due to (Hj). Protons (Hk) appear as a doublet in the aromatic region
because they are vicinal to one another. Protons (Hj) appear as an aromatic doublet at 7.5
ppm and they are identical protons that give a doublet because of the vicinal proton
labeled (Hi). Protons (Hk) are identical, aromatic protons that give a singlet peak at 6.4
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ppm. This peak occurs as a singlet because there are no vicinal protons. The two protons
(Hm) correspond to the identical phenol groups and appear as a singlet at 9.2 ppm.
Because these protons are directly bonded to electronegative oxygen atoms, they are
extremely deshielded and show up downfield. Protons (Hn) occur as an aromatic singlet
at 6.1 ppm due to the deshielding effects of aromatics and the peak is a singlet because
there are no vicinal protons. The main impurity in this spectra is labeled with a “*” and it
is water, which appears as a singlet around 3.4.
Conclusions
The goal of this research was to synthesize more biologically relevant derivatives
of resveratrol. The objective was to adjust the functional groups of a derivative in order to
improve its ability to enter the cell as well as improve its binding ability to HSA,
therefore, increasing the effectiveness of the derivative as well as its therapeutic potential.
Three derivatives were synthesized, (E)-methyl 4-(4-(3,5-di-hydroxy-styryl)-phenoxy)butanoate, (E)-ethyl 6-(4-(3,5-dihydroxystyryl)phenoxy)hexanoate, and (E)-ethyl 8-(4(3,5-dihydroxystyryl)phenoxy)octanoate. The same synthesis steps were followed and all
three derivatives were purified by column chromatography then verified using NMR
spectroscopy. While all three compounds were successfully synthesized, only derivative 3
was pure enough to be used for the next step in the project, which entails testing the
binding affinity of the derivative for human serum albumin, (HSA). Derivative 3 was
further analyzed through confocal raman spectroscopy; however, there was some laser
damage to the sample and a readable spectra could not be generated. The damage to the
sample; however, indicated the presence of a conjugated phenyl system that one would
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expect from derivative 3. The next aim of this research to investigate derivative 3’s ability
to enter the cell as well as to to assay the binding ability of derivative 3 with HSA in the
hopes of improving resveratrol’s anti-tumor properties. Derivatives 1 and 2 need to be
further purified through column chromatography using a more polar solvent system and
reevaluated using NMR spectroscopy. Once these three derivatives are isolated to the
necessary purity, their binding affinities can be properly tested within a biological setting.
The protein HSA is fluorescent because of a tryptophan residue and this fluorescence is
quenched when HSA binds with resveratrol, because of this the binding affinity can be
assessed and calculated.19 This testing will provide insight into how the length of the
alkyl chain affects both the molecule’s ability to enter the cell and the binding ability of
the molecule to HSA. Future work will also include synthesizing derivatives with
different functional groups to determine how these moieties impact the binding affinity
with HSA. Such biological studies would provide useful information about the ability of
these derivatives to aid in the treatment of cancer, alzheimer’s disease, heart disease, as
well as many other conditions. Though resveratrol has been shown to be extremely
beneficial with regards to many of these diseases and disorders, more biologically
available and active derivatives may prove useful as more efficient therapeutics.
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APPENDICES
Appendix A: 1H NMR spectrum of compound 1 in DMSO
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Appendix B: 1H NMR spectrum of compound 2 in DMSO
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Appendix C: 1H NMR spectrum of compound 3b in DMSO
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Appendix D: 13C NMR spectrum of compound 3b in DMSO
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Appendix E:1H NMR spectrum of compound 3a in CDCl3
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Appendix F: 1H NMR spectrum of compound 3a in DMSO
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Appendix G: 13C NMR spectrum of compound 3a in CDCl3
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Appendix H: 1H NMR spectrum of 8-bromooctanoic acid in CDCl3
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Appendix I: 13C NMR spectrum of 8 bromooctanoic acid in DMSO
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Appendix J: 1H NMR spectrum of resveratrol in DMSO
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Appendix K: 13C NMR spectrum of resveratrol in DMSO
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